AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.

According to a new comprehensive report from The Insight Partners, the global biologics market is expected to reach U.S.$ ...

We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical ... and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, ...

Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG are ...

The Global Liver Fibrosis Treatment Industry, valued at USD 16.43 Billion in 2022, is on the brink of an extraordinary surge, ...

The Medical Advertising Hall of Fame (MAHF) announced its 2025 inductees Thursday morning. The organization is inducting ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and ...

Earlier this month, I included a “spoiler alert” in one of our notes saying that we’d talk more about healthcare stocks. Today is that day. When it comes to an ETF, the Health Care Select Sector SPDR ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

Dear reader, market forecasts for 2030 indicate a significanttransformation in the global pharmaceutical landscape, with ...